Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 24 | 2014 | 193 | 3.120 |
Why?
|
| Muscle, Skeletal | 19 | 2014 | 282 | 2.390 |
Why?
|
| Muscle Fibers, Skeletal | 8 | 2014 | 64 | 1.810 |
Why?
|
| Oxidative Stress | 11 | 2019 | 938 | 1.620 |
Why?
|
| Apoptosis | 9 | 2016 | 1398 | 1.400 |
Why?
|
| Cystine | 3 | 2013 | 14 | 1.170 |
Why?
|
| Nicotine | 6 | 2018 | 257 | 1.160 |
Why?
|
| Acetylcysteine | 3 | 2011 | 62 | 1.070 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 5 | 2013 | 77 | 0.910 |
Why?
|
| Myocytes, Cardiac | 2 | 2016 | 166 | 0.830 |
Why?
|
| Fatty Liver | 5 | 2019 | 64 | 0.800 |
Why?
|
| Aging | 5 | 2013 | 664 | 0.800 |
Why?
|
| Sarcopenia | 2 | 2013 | 10 | 0.800 |
Why?
|
| Satellite Cells, Skeletal Muscle | 3 | 2006 | 8 | 0.750 |
Why?
|
| Antioxidants | 3 | 2013 | 416 | 0.700 |
Why?
|
| Mice, Inbred C57BL | 13 | 2019 | 1609 | 0.690 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2010 | 86 | 0.680 |
Why?
|
| Mitochondria | 3 | 2014 | 487 | 0.660 |
Why?
|
| Signal Transduction | 8 | 2018 | 1908 | 0.640 |
Why?
|
| Receptors, Notch | 3 | 2014 | 33 | 0.510 |
Why?
|
| Parabiosis | 1 | 2014 | 2 | 0.490 |
Why?
|
| Muscle Development | 2 | 2014 | 45 | 0.490 |
Why?
|
| Selenomethionine | 2 | 2011 | 10 | 0.470 |
Why?
|
| Male | 35 | 2019 | 20025 | 0.460 |
Why?
|
| Prediabetic State | 1 | 2014 | 53 | 0.450 |
Why?
|
| Caspase 2 | 2 | 2014 | 7 | 0.450 |
Why?
|
| Spermine | 2 | 2010 | 64 | 0.440 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 105 | 0.440 |
Why?
|
| Glutathione | 2 | 2010 | 179 | 0.420 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2011 | 95 | 0.420 |
Why?
|
| Hypertrophy | 5 | 2014 | 32 | 0.420 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.410 |
Why?
|
| Minocycline | 1 | 2011 | 5 | 0.400 |
Why?
|
| Dietary Fats | 2 | 2011 | 119 | 0.390 |
Why?
|
| Maternal Exposure | 1 | 2011 | 33 | 0.390 |
Why?
|
| Animals | 19 | 2019 | 15081 | 0.380 |
Why?
|
| Mice | 14 | 2019 | 5913 | 0.380 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 66 | 0.380 |
Why?
|
| Myostatin | 4 | 2009 | 63 | 0.380 |
Why?
|
| Inflammation | 2 | 2014 | 618 | 0.360 |
Why?
|
| Body Composition | 9 | 2011 | 162 | 0.340 |
Why?
|
| Down-Regulation | 1 | 2011 | 435 | 0.340 |
Why?
|
| Muscular Diseases | 1 | 2009 | 20 | 0.330 |
Why?
|
| Cocaine | 1 | 2011 | 232 | 0.320 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2018 | 58 | 0.310 |
Why?
|
| Cardiotoxins | 1 | 2007 | 2 | 0.310 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 1371 | 0.310 |
Why?
|
| Receptors, Androgen | 2 | 2004 | 126 | 0.290 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2014 | 115 | 0.280 |
Why?
|
| Obesity | 2 | 2014 | 1067 | 0.280 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 893 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2011 | 152 | 0.270 |
Why?
|
| Enzyme Activation | 4 | 2010 | 444 | 0.260 |
Why?
|
| Nitric Oxide | 1 | 2007 | 316 | 0.260 |
Why?
|
| Hepatocytes | 3 | 2014 | 75 | 0.240 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 730 | 0.230 |
Why?
|
| Organ Size | 3 | 2014 | 157 | 0.220 |
Why?
|
| Weight Loss | 5 | 2006 | 131 | 0.210 |
Why?
|
| Humans | 29 | 2019 | 37093 | 0.210 |
Why?
|
| Phosphorylation | 3 | 2016 | 928 | 0.190 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2011 | 77 | 0.190 |
Why?
|
| Double-Blind Method | 8 | 2005 | 286 | 0.180 |
Why?
|
| Adult | 19 | 2014 | 11712 | 0.170 |
Why?
|
| Cotinine | 1 | 2019 | 43 | 0.170 |
Why?
|
| Aldehydes | 2 | 2010 | 69 | 0.170 |
Why?
|
| HIV Infections | 7 | 2006 | 2303 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 52 | 0.160 |
Why?
|
| Menstrual Cycle | 1 | 1998 | 35 | 0.160 |
Why?
|
| Myogenin | 2 | 2009 | 5 | 0.150 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2009 | 43 | 0.150 |
Why?
|
| Triglycerides | 3 | 2014 | 138 | 0.150 |
Why?
|
| Models, Biological | 3 | 2016 | 677 | 0.150 |
Why?
|
| Benzamides | 1 | 2018 | 78 | 0.150 |
Why?
|
| Placebos | 3 | 2014 | 37 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2016 | 33 | 0.140 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 32 | 0.140 |
Why?
|
| Middle Aged | 14 | 2014 | 10129 | 0.140 |
Why?
|
| Caspases | 1 | 2016 | 147 | 0.140 |
Why?
|
| Body Weight | 3 | 2014 | 434 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2006 | 1039 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 70 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 3 | 2003 | 197 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 149 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 218 | 0.120 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cell Count | 2 | 2006 | 135 | 0.120 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2003 | 33 | 0.120 |
Why?
|
| Microscopy, Electron | 2 | 2006 | 209 | 0.120 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 9 | 0.120 |
Why?
|
| Lipolysis | 1 | 2014 | 18 | 0.120 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 42 | 0.120 |
Why?
|
| Pyrazines | 1 | 2014 | 24 | 0.120 |
Why?
|
| Adipose Tissue | 2 | 2014 | 177 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 153 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 146 | 0.110 |
Why?
|
| Blotting, Western | 3 | 2019 | 859 | 0.110 |
Why?
|
| Mice, Knockout | 2 | 2019 | 933 | 0.110 |
Why?
|
| Hypogonadism | 2 | 2004 | 21 | 0.110 |
Why?
|
| Muscle Fibers, Fast-Twitch | 2 | 2003 | 7 | 0.110 |
Why?
|
| Luteinizing Hormone | 6 | 2005 | 63 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2013 | 1369 | 0.110 |
Why?
|
| HIV Wasting Syndrome | 2 | 2004 | 8 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2014 | 208 | 0.110 |
Why?
|
| Reference Values | 3 | 2004 | 212 | 0.100 |
Why?
|
| Imidazoles | 2 | 2009 | 126 | 0.100 |
Why?
|
| Lipogenesis | 1 | 2011 | 18 | 0.100 |
Why?
|
| Pyridines | 2 | 2009 | 116 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2011 | 31 | 0.100 |
Why?
|
| Mice, Obese | 3 | 2018 | 40 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 227 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2010 | 35 | 0.090 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 129 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 854 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 133 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 433 | 0.090 |
Why?
|
| Heart | 1 | 2011 | 180 | 0.090 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2005 | 20 | 0.090 |
Why?
|
| Female | 8 | 2014 | 20969 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2011 | 1618 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2010 | 130 | 0.080 |
Why?
|
| Glucose | 1 | 2010 | 230 | 0.080 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2008 | 16 | 0.080 |
Why?
|
| Caspase 9 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Risk Factors | 2 | 2014 | 3562 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 169 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 169 | 0.070 |
Why?
|
| Spermatozoa | 1 | 2008 | 200 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2019 | 550 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 940 | 0.070 |
Why?
|
| Insulin Resistance | 2 | 2006 | 184 | 0.070 |
Why?
|
| Cell Death | 1 | 2007 | 267 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 24 | 0.070 |
Why?
|
| Rats | 2 | 2011 | 3483 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 41 | 0.070 |
Why?
|
| Pregnancy | 1 | 2011 | 1549 | 0.070 |
Why?
|
| Aged | 7 | 2006 | 6741 | 0.070 |
Why?
|
| Biopsy | 1 | 2006 | 164 | 0.070 |
Why?
|
| Cell Division | 1 | 2006 | 307 | 0.060 |
Why?
|
| Postmenopause | 1 | 2005 | 128 | 0.060 |
Why?
|
| Leuprolide | 1 | 2004 | 8 | 0.060 |
Why?
|
| Androstenedione | 1 | 2004 | 17 | 0.060 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2004 | 34 | 0.060 |
Why?
|
| Sexual Behavior | 3 | 2005 | 609 | 0.060 |
Why?
|
| Adolescent | 7 | 2006 | 5363 | 0.060 |
Why?
|
| Androgens | 1 | 2004 | 89 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2003 | 32 | 0.060 |
Why?
|
| Affect | 1 | 2005 | 152 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 60 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2003 | 17 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1198 | 0.060 |
Why?
|
| Cell Size | 1 | 2003 | 44 | 0.060 |
Why?
|
| Oxymetholone | 1 | 2002 | 1 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 623 | 0.050 |
Why?
|
| Dihydrotestosterone | 2 | 1999 | 29 | 0.050 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2002 | 10 | 0.050 |
Why?
|
| Anabolic Agents | 1 | 2002 | 18 | 0.050 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2002 | 11 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 602 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2004 | 513 | 0.050 |
Why?
|
| Cognition | 1 | 2005 | 398 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1998 | 43 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2003 | 366 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 562 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2231 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2004 | 1518 | 0.050 |
Why?
|
| Bed Rest | 1 | 1999 | 3 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2001 | 120 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1207 | 0.040 |
Why?
|
| Muscular Atrophy | 1 | 1999 | 13 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1998 | 8 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 481 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 233 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Dialysis | 1 | 1998 | 6 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 1999 | 1130 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 1998 | 65 | 0.040 |
Why?
|
| Energy Intake | 2 | 2011 | 170 | 0.040 |
Why?
|
| Exercise | 2 | 2001 | 613 | 0.040 |
Why?
|
| Administration, Topical | 2 | 2006 | 40 | 0.030 |
Why?
|
| Administration, Cutaneous | 3 | 2001 | 43 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 935 | 0.030 |
Why?
|
| HIV-1 | 1 | 1998 | 706 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 30 | 0.030 |
Why?
|
| Animal Feed | 1 | 2012 | 43 | 0.030 |
Why?
|
| Insulin | 2 | 2006 | 236 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2011 | 21 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 105 | 0.030 |
Why?
|
| Hormones | 2 | 2001 | 55 | 0.020 |
Why?
|
| Absorptiometry, Photon | 2 | 2002 | 75 | 0.020 |
Why?
|
| Adiposity | 1 | 2011 | 154 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2002 | 353 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 479 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 12 | 0.020 |
Why?
|
| Fever | 1 | 2008 | 57 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 136 | 0.020 |
Why?
|
| Testis | 1 | 2008 | 187 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2006 | 13 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2005 | 3 | 0.020 |
Why?
|
| Gels | 1 | 2005 | 42 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 88 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 63 | 0.020 |
Why?
|
| Menstruation | 1 | 2004 | 10 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2004 | 59 | 0.020 |
Why?
|
| California | 1 | 2006 | 476 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2004 | 66 | 0.020 |
Why?
|
| Exercise Test | 1 | 2004 | 67 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 610 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 623 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2003 | 51 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 349 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 212 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 129 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 708 | 0.010 |
Why?
|
| Stem Cells | 1 | 2003 | 141 | 0.010 |
Why?
|
| Fasting | 1 | 2002 | 54 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 3 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2002 | 5 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2001 | 18 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2002 | 79 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 2002 | 18 | 0.010 |
Why?
|
| Body Water | 1 | 2001 | 26 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 515 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2001 | 39 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 97 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 1033 | 0.010 |
Why?
|
| Half-Life | 1 | 2001 | 54 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 587 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 617 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 116 | 0.010 |
Why?
|
| Lipids | 1 | 2002 | 235 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 205 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 481 | 0.010 |
Why?
|
| Biological Availability | 1 | 2000 | 88 | 0.010 |
Why?
|
| Thigh | 1 | 2000 | 11 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2000 | 21 | 0.010 |
Why?
|
| Head-Down Tilt | 1 | 1999 | 4 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 898 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 262 | 0.010 |
Why?
|
| Thyroxine | 1 | 1999 | 19 | 0.010 |
Why?
|
| Weightlessness Simulation | 1 | 1999 | 21 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1999 | 17 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1418 | 0.010 |
Why?
|
| Introns | 1 | 1998 | 75 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 124 | 0.010 |
Why?
|
| Exons | 1 | 1998 | 88 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 238 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 188 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 325 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 225 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 477 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 474 | 0.010 |
Why?
|
| Base Sequence | 1 | 1998 | 997 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 2379 | 0.010 |
Why?
|
| Emotions | 1 | 1998 | 220 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 1568 | 0.010 |
Why?
|
| Child | 1 | 2003 | 3131 | 0.010 |
Why?
|